Oxalo Therapeutics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 2

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $1M

  • Investors
  • 5

Oxalo Therapeutics General Information

Description

Developer of a novel drug therapy designed to treat and prevent recurrent kidney stones. The company's therapy is derived from a gut bacterium to prevent and treat diseases such as hyperoxaluria and oxalate-based kidney stones, as well as renal diseases caused by high levels of oxalate in the body, enabling healthcare professionals to remove oxalate safely from the body of a patient and consequently prevent the recurrence of stones.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Corporate Office
  • Polsky Exchange, 1452 East 53rd Street
  • 2nd Floor
  • Chicago, IL 60615
  • United States
+1 (312)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Polsky Exchange, 1452 East 53rd Street
  • 2nd Floor
  • Chicago, IL 60615
  • United States
+1 (312)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Oxalo Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Grant 15-Apr-2022 $1M Completed Startup
6. Grant 28-Jun-2019 Completed Startup
5. Accelerator/Incubator 17-Oct-2018 Completed Startup
4. Grant 19-Sep-2018 Completed Startup
3. Accelerator/Incubator 01-May-2018 Completed Startup
2. Accelerator/Incubator 06-Dec-2017 $250K $250K Completed Startup
1. University Spin-Out 01-Jan-2017 Completed Startup
To view Oxalo Therapeutics’s complete valuation and funding history, request access »

Oxalo Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Oxalo Therapeutics Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
US National Science Foundation Accelerator/Incubator
MassChallenge Accelerator/Incubator
National Institutes of Health Government
Polsky Center for Entrepreneurship and Innovation at the University of Chicago Accelerator/Incubator Minority
University of Chicago University
To view Oxalo Therapeutics’s complete investors history, request access »

Oxalo Therapeutics FAQs

  • When was Oxalo Therapeutics founded?

    Oxalo Therapeutics was founded in 2017.

  • Where is Oxalo Therapeutics headquartered?

    Oxalo Therapeutics is headquartered in Chicago, IL.

  • What is the size of Oxalo Therapeutics?

    Oxalo Therapeutics has 2 total employees.

  • What industry is Oxalo Therapeutics in?

    Oxalo Therapeutics’s primary industry is Drug Discovery.

  • Is Oxalo Therapeutics a private or public company?

    Oxalo Therapeutics is a Private company.

  • What is Oxalo Therapeutics’s current revenue?

    The current revenue for Oxalo Therapeutics is .

  • How much funding has Oxalo Therapeutics raised over time?

    Oxalo Therapeutics has raised $350K.

  • Who are Oxalo Therapeutics’s investors?

    US National Science Foundation, MassChallenge, National Institutes of Health, Polsky Center for Entrepreneurship and Innovation at the University of Chicago, and University of Chicago have invested in Oxalo Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process